Adaptimmune Therapeutics plc (ADAP)
ADAP Price and Sentiment
ADAP Latest news
Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society annual meeting. The Company says that the trial will meet its primary endpoint for efficacy, and the data will be used to support marketing application filing for afami-cel next year.
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS2021-11-11 09:00
- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year -
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript2021-11-04 14:47
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript
These two small-cap cancer companies would be a perfect fit for Pfizer.
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment -
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) that same day (details below).
These two novel-drug makers could be top takeover targets next year.
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -
Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.